NasdaqGS - Delayed Quote USD

Crinetics Pharmaceuticals, Inc. (CRNX)

49.38 +1.45 (+3.03%)
At close: May 14 at 4:00 PM EDT
48.34 -1.04 (-2.11%)
After hours: May 14 at 7:30 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
1,974.00
4,013.00
4,737.00
1,078.00
--
Operating Expense
250,133.00
226,621.00
172,619.00
108,780.00
74,953.00
Operating Income
-248,159.00
-222,608.00
-167,882.00
-107,702.00
-74,953.00
Net Non Operating Interest Income Expense
18,718.00
13,436.00
4,317.00
157.00
991.00
Other Income Expense
-6,023.00
-5,357.00
-353.00
-96.00
150.00
Pretax Income
-235,464.00
-214,529.00
-163,918.00
-107,641.00
-73,812.00
Net Income Common Stockholders
-235,464.00
-214,529.00
-163,918.00
-107,641.00
-73,812.00
Diluted NI Available to Com Stockholders
-235,464.00
-214,529.00
-163,918.00
-107,641.00
-73,812.00
Basic EPS
-3.77
-3.69
-3.15
-2.80
-2.42
Diluted EPS
-3.77
-3.69
-3.15
-2.80
-2.42
Basic Average Shares
62,666.25
58,071.00
51,982.00
38,436.00
30,448.00
Diluted Average Shares
62,666.25
58,071.00
51,982.00
38,436.00
30,448.00
Total Operating Income as Reported
-248,159.00
-222,608.00
-167,882.00
-107,702.00
-74,953.00
Total Expenses
250,133.00
226,621.00
172,619.00
108,780.00
74,953.00
Net Income from Continuing & Discontinued Operation
-235,464.00
-214,529.00
-163,918.00
-107,641.00
-73,812.00
Normalized Income
-235,464.00
-214,529.00
-164,518.00
-107,641.00
-73,812.00
Interest Income
18,718.00
13,436.00
4,317.00
157.00
991.00
Net Interest Income
18,718.00
13,436.00
4,317.00
157.00
991.00
EBIT
-248,159.00
-222,608.00
-167,882.00
-107,702.00
-74,953.00
EBITDA
-246,870.00
-221,510.00
-166,899.00
-106,780.00
-74,005.00
Reconciled Depreciation
1,289.00
1,098.00
983.00
922.00
948.00
Net Income from Continuing Operation Net Minority Interest
-235,464.00
-214,529.00
-163,918.00
-107,641.00
-73,812.00
Total Unusual Items Excluding Goodwill
--
--
600.00
--
--
Total Unusual Items
--
--
600.00
--
--
Normalized EBITDA
-246,870.00
-221,510.00
-167,499.00
-106,780.00
-74,005.00
12/31/2020 - 7/18/2018

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

MRUS Merus N.V.
44.77
-2.36%
 
JANX Janux Therapeutics, Inc.
47.91
-4.16%
 
CYTK Cytokinetics, Incorporated
59.36
+2.54%
 
DNLI Denali Therapeutics Inc.
19.75
+2.33%
 
SNDX Syndax Pharmaceuticals, Inc.
21.66
+3.29%
 
APGE Apogee Therapeutics, Inc.
54.00
+2.41%
 
RYTM Rhythm Pharmaceuticals, Inc.
40.38
+0.45%
 
ARVN Arvinas, Inc.
31.36
-0.67%
 
KRYS Krystal Biotech, Inc.
159.47
+3.00%
 
EWTX Edgewise Therapeutics, Inc.
17.44
-0.23%